Please login to the form below

Not currently logged in

Excellence in Rare Diseases and Orphan Drugs

Sponsored by

Back to Results


INSPIRE: Improving Outcomes in Paediatric Cardiology

by AbbVie with support from Lucid Group

Summary of work

Babies with congenital heart disease (CHD) present a wide range of anatomical abnormalities; uniting the diverse pathology is a risk of life-threatening complications and a paucity of research and investment. Without big funding, there are few multinational trials and international congresses that generate robust data and showcase results: there is limited infrastructure to enable paediatric cardiologists across the world to connect. This lack of connection hampers collaborative research, and honest expertise and experience sharing, impeding advances in quality of care.

INSPIRE was established to drive implementation of a core set of clinical behaviours underpinning optimal clinical management of babies with CHD. INSPIRE (International Specialist Paediatric Cardiology Care) mapped key components and behaviours that contribute to optimal care and worked with global leaders to develop small-group, practical, in-clinic training blending traditional medical education and peer-to-peer sharing in an open, honest and safe environment. A flexible approach addressed variations in global clinic models/challenges and a tailored agenda addressed delegates’ barriers. Four months later, 100% of delegates were using INSPIRE learnings to inform their clinical practice with 82% noting advances to their clinical management strategies aligned to the core behaviours. Together INSPIRE has helped up to 7,700 vulnerable paediatric patients per year receive improved care.

Judges' comments

INSPIRE was a great initiative with significant global scale, which looked at outcomes and impact beyond the short term. It had really strong KPI setting and monitoring.


Greater than the Sum of its Parts - by Jazz Pharmaceuticals

Highly commended


INSPIRE: Improving Outcomes in Paediatric Cardiology - by AbbVie with support from Lucid Group

Palmoplantar Pustulosis Augmented Reality Tool - by Boehringer Ingelheim with support from OPEN Health

RAREfest - by Cambridge Rare Disease Network with support from Havas Life Medicom

Chronicity in Acute Times: Cablivi Access Challenge - by Sanofi Genzyme

Key dates

Entry deadline 26 August 2022
Extended entry deadline 2 September 2022*
*additional fee applies
Judging Day 6 October 2022
Company/Team of the Year Interviews 21 October 2022
PMEA Event 23 November 2022